"The U.S. Food and Drug Administration today approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections.
Orbactiv is approved to treat patients with acute bacterial skin and skin structure infections (ABSS"...
Topically applied LoKara™ Lotion (desonide lotion 0.05%) can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).
LoKara™ Lotion (desonide lotion 0.05%) is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 9/27/2011
Additional LoKara Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.